Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 4/2017

01-07-2017 | Review Article

The role of miR-130a in cancer

Authors: He-da Zhang, Lin-hong Jiang, Da-wei Sun, Jian Li, Zhen-ling Ji

Published in: Breast Cancer | Issue 4/2017

Login to get access

Abstract

MicroRNAs (miRs) are short and highly conserved non-coding RNAs molecules consisting of 18–25 nucleotides that regulate gene expression at post-transcriptional level by direct binding to complementary binding sites within the 3′untranslated region (3′UTR) of target mRNAs. New evidences have demonstrated that miRNAs play an important role in diverse physiological processes, including regulating cell growth, apoptosis, metastasis, drug resistance, and invasion. In chromosomes 11 and 22 of the miR-130 family, paralogous miRNA sequences, miR-130a and miR-130b are situated, respectively. MiR-130a has participated in different pathogenesis, including hepatocellular carcinoma, cervical cancer, ovarian cancer, glioblastoma, prostate carcinoma, leukemia, etc. Most important of all, more and more evidences indicate that miR-130a is associated with drug resistance and acts as an intermediate in PI3 K/Akt/PTEN/mTOR, Wnt/β-catenin and NF-kB/PTEN drug resistance signaling pathways. Drug resistance has emerged as a major obstacle to successful treatment of cancer nowadays and in this review, we will reveal the function of miR-130a in cancer, especially in drug resistance. Therefore, it will provide a new therapeutic target for the treatment of cancer, especially in chemotherapy.
Literature
1.
Torre Lindsey A, Bray Freddie, Siegel Rebecca L, et al. Global cancer statistics. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed
2.
3.
Wang D, Qiu C, Zhang H, Wang J, Cui Q, Yin Y. Human microRNA oncogenes and tumor suppressors show significantly different biological patterns: from functions to targets. PLoS One. 2010;5:e13067.CrossRefPubMedPubMedCentral
4.
Giannakakis A, Coukos G, Hatzigeorgiou A, Sandaltzopoulos R, Zhang L. miRNA genetic alterations in human cancers. Expert Opin Biol Ther. 2007;7:1375–86.CrossRefPubMed
5.
Zhang HD, Jiang LH, Sun DW, Tang JH. MiR-139-5p: promising biomarker for cancer. Tumour Biol. 2015;36:1355–65.CrossRefPubMed
6.
7.
Chen X, Lu P, Wang DD, Yang SJ, Wu Y, Shen HY. The role of miRNAs in drug resistance and prognosis of breast cancer formalin-fixed paraffin-embedded tissues. Gene. 2016;595:221–6.CrossRefPubMed
8.
Suresh S, McCallum L, Lu W, Lazar N, Perbal B, Irvine AE. MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML. J Cell Commun Signal. 2011;5:183–91.CrossRefPubMedPubMedCentral
9.
Ishihara K, Sasaki D, Tsuruda K, Inokuchi N, Nagai K, Hasegawa H, et al. Impact of miR-155 and miR-126 as novel biomarkers on the assessment of disease progression and prognosis in adult T-cell leukemia. Cancer Epidemiol. 2012;36:560–5.CrossRefPubMed
10.
Sand M, Skrygan M, Sand D, Georgas D, Hahn SA, Gambichler T, et al. Expression of microRNAs in basal cell carcinoma. Br J Dermatol. 2012;167:847–55.CrossRefPubMed
11.
Jiang H, Yu WW, Wang LL, Peng Y. MiR-130a acts as a potential diagnostic biomarker and promotes gastric cancer migration, invasion and proliferation by targeting RUNX3. Oncol Rep. 2015;34:1153–61.PubMedPubMedCentral
12.
Wang XC, Tian LL, Wu HL, Jiang XY, Du LQ, Zhang H, et al. Expression of miRNA-130a in nonsmall cell lung cancer. Am J Med Sci. 2010;340:385–8.CrossRefPubMed
13.
Chen J, Yan D, Wu W, et al. MicroRNA-130a promotes the metastasis and epithelial-mesenchymal transition of osteosarcoma by targeting PTEN. Oncol Rep. 2016;35:3285–92.PubMed
14.
Liu SG, Qin XG, Zhao BS, Zhu J, Ye W, Shu Q. Differential expression of miRNAs in esophageal cancer tissue. Oncol Lett. 2013;5:1639–42.PubMedPubMedCentral
15.
Ratert N, Meyer HA, Jung M. miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. J Mol Diagn. 2013;15:695–705.CrossRefPubMed
16.
Zhang X, Huang L, Zhao Y, Tan W. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly. Acta Biochim Biophys Sin (Shanghai). 2013;45:995–1001.CrossRef
17.
Li B, Huang P, Qiu J, Liao Y, Hong J, Yuan Y. MicroRNA-130a is down-regulated in hepatocellular carcinoma and associates with poor prognosis. Med Oncol. 2014;31:230.CrossRefPubMed
18.
Pan Y, Wang R, Zhang F, Chen Y, Lv Q, Long G, et al. MicroRNA-130a inhibits cell proliferation, invasion and migration in human breast cancer by targeting the RAB5A. Int J Clin Exp Pathol. 2015;8:384–93.PubMedPubMedCentral
19.
He L, Wang HY, Zhang L, Huang L, Li JD, Xiong Y, et al. Prognostic significance of low DICER expression regulated by miR-130a in cervical cancer. Cell Death Dis. 2014;5:e1205.CrossRefPubMedPubMedCentral
20.
Qiu S, Lin S, Hu D, Feng Y, Tan Y, Peng Y. Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med. 2013;11:10.CrossRefPubMedPubMedCentral
21.
Boll K, Reiche K, Kasack K, Mörbt N, Kretzschmar AK, Tomm JM, et al. MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene. 2013;32:277–85.CrossRefPubMed
22.
Kovaleva V, Mora R, Park YJ, Plass C, Chiramel AI, Bartenschlager R, et al. miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells. Cancer Res. 2012;72:1763–72.CrossRefPubMed
23.
Cui XY, Guo YJ, Yao HR. Analysis of microRNA in drug- resistant breast cancer cell line MCF-7/ADR. Nan Fang Yi Ke Da Xue Xue Bao. 2008;28:1813–5.PubMed
24.
Chen C, Wang HJ, Yang LY, Jia XB, Xu P, Chen J, et al. Expression of MiR-130a in serum samples of patients with epithelial ovarian cancer and its association with platinum resistance. Sichuan Da Xue Xue Bao Yi Xue Ban. 2016;47:60–3.PubMed
25.
Zhou YM, Liu J, Sun W. MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines. Asian Pac J Cancer Prev. 2014;15:1391–6.CrossRefPubMed
26.
Yuan WX, Gui YX, Na WN, et al. Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients. Oncol Lett. 2016;11:423–32.PubMed
27.
Liu Y, Li Y, Wang R, Chao J, Yang X. MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells. J Exp Clin Cancer Res. 2016;35:19.CrossRefPubMedPubMedCentral
28.
Xu N, Shen C, Luo Y, Xia L, Xue F, Xia Q, Zhang J. Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochem Biophys Res Commun. 2012;425:468–72.CrossRefPubMed
29.
Fujita Y, Kojima T, Kawakami K, Mizutani K, Kato T, Deguchi T, et al. miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells. Prostate. 2015;75:1568–78.CrossRefPubMed
30.
Lanzetti L, Palamidessi A, Areces L, Areces L, Scita G, Di Fiore PP. Rab5 is a signalling GTPase involved in actin remodelling by receptor tyrosine kinases. Nature. 2004;429:309–14.CrossRefPubMed
31.
Li QL, Ito K, Sakakura C, Ki Inoue, Chi XZ, Lee KY, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 2002;109:113–24.CrossRefPubMed
32.
Jo MJ, Lee JR, Cho IJ, Kim YW, Kim SC. Roots of Erigeron annuus attenuate acute inflammation as mediated with the inhibition of NF- kappa B-associated nitric oxide and prostaglandin E2 production. Evid Based Complement Alternat Med. 2013;2013:297427.CrossRefPubMedPubMedCentral
33.
Park SW, Cho C, Cho BN, Kim Y, Goo TW, Kim YI. 15-deoxy-delta12,14-prostaglandin J 2 down-regulates activin-induced activin receptor, smad, and cytokines expression via suppression of NF- kappa B and MAPK signaling in HepG2 cells. PPAR Res. 2013;2013:751261.CrossRefPubMedPubMedCentral
34.
Ling H, Gray CB, Zambon AC, Grimm M, Gu Y, Dalton N, et al. Ca2+/calmodulin-dependent protein kinase II deltamediates myocardial ischemia/reperfusion injury through nuclear factor-kappaB. Circ Res. 2013;112:935–44.CrossRefPubMedPubMedCentral
35.
Zhang J, Chen J, Yang J, Xu CW, Pu P, Ding JW, et al. Resveratrol attenuates oxidative stress induced by balloon injury in the rat carotid artery through actions on the ERK1/2 and NF-kappa B pathway. Cell Physiol Biochem. 2013;31:230–41.CrossRefPubMed
36.
37.
Feng Y, Zhou S, Li G, Hu C, Zou W, Zhang H, et al. Nuclear factor-κB-dependent microRNA-130a upregulation promotes cervical cancer cell growth by targeting phosphatase and tensin homolog. Arch Biochem Biophys. 2016;598:57–65.CrossRefPubMed
38.
Majetschak M, Obertacke U, Schade FU, Bardenheuer M, Voggenreiter G, Bloemeke B, et al. Tumor necrosis factor gene polymorphisms, leukocyte function, and sepsis susceptibility in blunt trauma patients. Clin Diagn Lab Immunol. 2002;9:1205–11.PubMedPubMedCentral
39.
Balkwill F, Joffroy C. TNF: a tumor-suppressing factor or a tumor promoting factor? Future Oncol. 2010;6:1833–6.CrossRefPubMed
40.
Hagemann T, Robinson SC, Schulz M, Trümper L, Balkwill FR, Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-α dependent up-regulation of matrix metalloproteases. Carcinogenesis. 2004;25:1543–9.CrossRefPubMed
41.
Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 2000;14:2123–33.CrossRefPubMed
42.
Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. 2004;23:101–17.CrossRefPubMed
43.
Häger M, Pedersen CC, Larsen MT, Andersen MK, Hother C, Grønbæk K, et al. MicroRNA-130a-mediated down-regulation of Smad4 contributes to reduced sensitivity to TGF-β1 stimulation in granulocytic precursors. Blood. 2011;118:6649–59.CrossRefPubMed
44.
Chang CW, Yu JC, Hsieh YH, Yao CC, Chao JI, Chen PM, et al. MicroRNA-30a increases tight junction protein expression to suppress the epithelial-mesenchymal transition and metastasis by targeting Slug in breast cancer. Oncotarget. 2016;7:16462–78.PubMedPubMedCentral
45.
Parsons R, Simpson L. PTEN and cancer. Methods Mol Biol. 2003;222:147–66.PubMed
46.
Nielsen-Preiss SM, Silva SR, Gillette JM. Role of PTEN and Akt in the regulation of growth and apoptosis in human osteoblastic cells. J Cell Biochem. 2003;90:964–75.CrossRefPubMed
47.
Hu Y, Xu S, Jin W, Yi Q, Wei W. Effect of the PTEN gene on adhesion, invasion and metastasis of osteosarcoma cells. Oncol Rep. 2014;32:1741–7.PubMed
48.
Wang Z, Dai X, Chen Y, et al. MiR-30a-5p is induced by Wnt/β-catenin pathway and promotes glioma cell invasion by repressing NCAM. Biochem Biophys Res Commun. 2015;465:374–80.CrossRefPubMed
49.
Wang W, Lin H, Zhou L, Sun C, Zhu Q, Zhao H, et al. MicroRNA-30a-3p inhibits tumor proliferation, invasiveness and metastasis and is downregulated in hepatocellular carcinoma. Eur J Surg Oncol. 2014;40:1586–94.CrossRefPubMed
50.
Li WF, Dai H, Ou Q, Zuo GQ, Liu CA. Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH/PTEN/AKT pathway. Tumour Biol. 2016;37:5885–95.CrossRefPubMed
51.
Schlessinger K, Hall A, Tolwinski N. Wnt signaling pathways meet Rho GTPases. Genes. 2009;23:265–77.CrossRef
52.
Scheel C, Eaton EN, Li SH, Reinhardt F, Kah KJ, Bell G, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell. 2011;145:926–40.CrossRefPubMedPubMedCentral
53.
Sharrard RM, Maitland NJ. Alternative splicing of the human PTEN/MMAC1/TEP1 gene. Biochim Biophys Acta. 2000;1494:282–5.CrossRefPubMed
54.
Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273:13375–8.CrossRefPubMed
55.
Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13:2905–27.CrossRefPubMed
56.
57.
Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006;127:125–37.CrossRefPubMed
58.
Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22:159–68.CrossRefPubMed
59.
Vazquez F, Sellers WR. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signalling. Biochim Biophys Acta. 2000;1470:M21–35.PubMed
60.
Yang L, Li N, Wang H, Jia X, Wang X, Luo J. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol Rep. 2012;28:592–600.PubMed
61.
Li NW, Wang HJ, Yang LY, Jia XB, Chen C, Wang X. Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines. Sichuan Da Xue Xue Bao Yi Xue Ban. 2013;44:865–70.PubMed
62.
Li N, Yang L, Wang H, Yi T, Jia X, Chen C, Xu P. MiR-130a and MiR-374a function as novel regulators of cisplatin resistance in human ovarian cancer A2780 cells. PLoS One. 2015;10:e0128886.CrossRefPubMedPubMedCentral
63.
Hu M, Liu Y, Deng C, Han R, Jia Y, Liu S, et al. Enhanced invasiveness in multidrug resistant leukemic cells is associated with overexpression of P-glycoprotein and cellular inhibitor of apoptosis protein. Leuk Lymphoma. 2011;52:1302–11.CrossRefPubMed
64.
Gottesman MM, Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett. 2006;580:998–1009.CrossRefPubMed
65.
Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L, et al. MiR-27a modulates MDR1/Pglycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol. 2010;119:125–30.CrossRefPubMed
66.
Ma JJ, Chen BL, Xin XY. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol. 2009;146:222–6.CrossRefPubMed
67.
Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res. 2000;60:5659–66.PubMed
68.
Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, et al. Reciprocal and complementary role of MET amplification and EGFR T790 M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res. 2010;16:5489–98.CrossRefPubMed
69.
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039–43.CrossRefPubMed
70.
Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res. 2006;12:3657–60.CrossRefPubMed
71.
Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 2009;16:498–509.CrossRefPubMedPubMedCentral
72.
Acunzo M, Visone R, Romano G, Veronese A, Lovat F, Palmieri D, et al. miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene. 2012;31:634–42.PubMed
73.
Chen CX, Hu Y, Li L. NRP1 is targeted by miR-130a and miR-130b, and is associated with multidrug resistance in epithelial ovarian cancer based on integrated gene network analysis. Mol Med Rep. 2016;13:188–96.PubMed
Metadata
Title
The role of miR-130a in cancer
Authors
He-da Zhang
Lin-hong Jiang
Da-wei Sun
Jian Li
Zhen-ling Ji
Publication date
01-07-2017
Publisher
Springer Japan
Published in
Breast Cancer / Issue 4/2017
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-017-0776-x

Other articles of this Issue 4/2017

Breast Cancer 4/2017 Go to the issue

Special Feature

Breast reconstruction and postmastectomy radiotherapy: complications by type and timing and other problems in radiation oncology

Original Article

The effects of complex exercise on shoulder range of motion and pain for women with breast cancer-related lymphedema: a single-blind, randomized controlled trial

Original Article

Accuracy assessment methods of tissue marker clip placement after 11-gauge vacuum-assisted stereotactic breast biopsy: comparison of measurements using direct and conventional methods

Original Article

Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial

Original Article

Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis

Special Feature

Post-mastectomy radiation therapy in breast cancer with 1–3 involved lymph nodes: the Pros
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits